The STEP program (currently comprising STEP 1 to STEP 8) is a collection of Phase 3 trials of 2.4 mg semaglutide administered subcutaneously once weekly in conjunction with different intensities of lifestyle interventions
Its power lies in its ability to tackle inflammation, repair damaged tissue, and correct cellular dysfunction simultaneously
Panthenol is famous due to its ability to go deeper into the skin's layers
#MacterInternational #Biosimilars #Semaglutide #HealthcareInnovation #DiabetesCare #rDNABiotechnology #PharmaExcellence Great So Macter rDNA Seglutide is the first rDNA-based Semaglutide in Pakistan after the Global Brand, great news for Patients and Physicians.the shifting of GLP-1 landscape in Pakistan - Congratulations Right Source, Right Dose
10.1038/tp.2013.14 9 FryeR
2013;27(3):303-313 Elam MB, Hunninghake DB, Davis KB, et al